comparemela.com

Page 6 - Suzanne Winter News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Accuray Announces Approval of the Tomo® C Radiation Treatment Delivery System by China s National Medical Products Administration

/PRNewswire/ Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo® C radiation therapy.

United statesBeth kaplanAccuray incorporatedPrnewswire accuray incorporatedChinese national medical products administrationWorld health organizationExchange commissionTomoc systemSuzanne winterPrivate securities litigation reform actAnnual reportRelations director

Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting

/PRNewswire/ Accuray Incorporated (NASDAQ: ARAY) announced today that the company has a 510(k) pending for an online adaptive therapy option , Cenos™, for.

United statesSan diegoBeth kaplanKarl ottoAccuray incorporatedPrnewswire accuray incorporatedAmerican society for radiation oncology annual meetingExchange commissionAccuray financial servicesAmerican societyRadiation oncologyAnnual meetingSuzanne winterLimbus contourAccuray highlightsFinancial services

Accuray Opens New Global Training Center at Madison, WI Headquarters to Advance Radiotherapy Treatment Techniques Amid Growing Demand for Precision Cancer Care

/PRNewswire/ Accuray Incorporated (NASDAQ: ARAY) announced today that the company has opened the doors of its new global training facility, the Accuray.

United statesAccuray cyberknifeBeth kaplanExchange commissionMicrolearning programPrnewswire accuray incorporatedAccuray centerAccuray exchange aexAccuray incorporatedAccuray exchangeSuzanne winterRadixact systemPrivate securities litigation reform actAnnual reportRelations director

Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market

/PRNewswire/ Accuray Incorporated (NASDAQ: ARAY) announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration.

United statesUnited kingdomBeth kaplanAccuray incorporatedEuropean unionDrug administrationNational cancer institutePrnewswire accuray incorporatedRadixact systemSuzanne winterCecilia de leeuwImportant safety informationHealth care amp hospitalsMedical pharmaceuticalsMedical equipmentFda approval

Accuray Reports Fourth Quarter and Fiscal 2023 Financial Results

/PRNewswire/ Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2023, ended June 30, 2023. Fourth.

United statesAli pervaizBeth kaplanRaman patelAccuray incorporated nasdaqPrnewswire accuray incorporatedExchange commissionEuropean unionAccuray incorporatedQuarter fiscalSuzanne winterChief executiveEnterprise resource planningChief financialInvestor relationsPrivate securities litigation reform act

vimarsana © 2020. All Rights Reserved.